Urea-based recirculation validation of the symmetrical palindrome catheter.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Jonczyk, M
- Althoff, C
- Slowinski, T
- Lieker, I
- Naik, M
- Auer, J
- Duka, E
- Hamm, B
- de Bucourt, M
Grupos
Abstract
BACKGROUND: High blood flow and low recirculation rates are central for adequate haemodialysis. A new symmetrical tip has been invented promising efficient haemodialysis even if the ports are reversed. OBJECTIVE: To evaluate access recirculation of the 'palindrome' catheter and to report initial experiences in a clinical setting. MATERIAL AND METHODS: After implantation of the new catheter in 20 patients (male: 14; female: 6; mean age 72 +/- 12.2), access recirculation was evaluated using the urea-based recirculation test. After 30 minutes of haemodialysis, ultrafiltration was stopped and arterial and venous samples were taken. Afterwards, the blood flow rate was reduced to 120 ml/min. Another systemic arterial blood sample was taken 10 seconds after the blood pump was switched off. RESULTS: All 20 interventions were performed successfully without complications. The average recirculation rate was 8.1% with a median of 2.5% ranging from 0 to 85.8%. Recirculation rates under 5% were measured in 13 patients and more than 10% recirculation were found in two patients. The median of days between catheter implantation and recirculation assessment was the day following implantation. CONCLUSION: The new symmetrical catheter presented low recirculation rates in a clinical setting. Since there is just a single tip, fluoroscopic placement in the right atrium is facilitated.
Datos de la publicación
- ISSN/ISSNe:
- 1755-6678, 1755-6686
- Tipo:
- Article
- Páginas:
- 242-246
- DOI:
- 10.1111/jorc.12210
- Factor de Impacto:
- 0,412 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Journal Of Renal Care WILEY
Citas Recibidas en Web of Science: 3
Documentos
- No hay documentos
Filiaciones
Keywords
- Central venous access; Haemodialysis catheter; Palindrome; Urea recirculation
Proyectos asociados
HECATOS. HEPATIC AND CARDIAC TOXICITY SYSTEMS MODELLING.
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
602156_HECATOS_PE_FP7-HEALTH-2013-INNOVATI . 2013
DISEÑO Y DESARROLLO DE UNA PLATAFORMA MULTIESCALA-IN VITRO-IN VIVO PARA LA PREVENCIÓN DE LA FRACTURA ÓSEA OSTEOPORÓTICA MEDIANTE CEMENTACIÓN FEMORAL: UNA HERRAMIENTA PRECLÍNICA
Investigador Principal: ÁNGEL ALBERICH BAYARRI
DPI2014-53401-C2-2-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2015
ENSAYO CLINICO EN FASE III, DE "THERASPHERE" INTRAARTERIAL PARA EL TRATAMIENTO DE PACIENTES CON CARCINOMA HEPATOCELULAR(CHC) NO RESECALBE.
Investigador Principal: DANIEL PÉREZ ENGUIX
TS-103 . 2016
ENSAYO CLÍNICO RANDOMIZADO, MULTICÉNTRICO FASE 1B/3 DE TALIMOGENE LAHERPAREPVEC EN COMBINACIÓN CON PEMBROLIZUMAB PARA EL TRATAMIENTO DE PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS DE CABEZA Y CUELLO METASTÁSICO O RECURRENTE.
Investigador Principal: JAVIER CABALLERO DAROQUI
20130232 . 2017
ENSAYO CLÍNICO PROSPECTIVO Y RANDOMIZADO SOBRE EL USO DE LA RADIOEMBOLIZACIÓN TRANSARTERIAL CON ITRIO 90 (THERASPHERE®) FRENTE AL TRATAMIENTO HABITUAL (SORAFENIB), EN EL TRATAMIENTO DE PACIENTES CON CARCINOMA HEPATOCELULAR EN ESTADIO AVANZADO Y TROMBOSIS PORTAL ASOCIADA.
Investigador Principal: DANIEL PÉREZ ENGUIX
TS-104
ESTUDIO DE FASE III, ALEATORIZADO, ABIERTO QUE COMPARA LA COMBINACIÓN DEL INHIBIDOR DE BRAF, (DABRAFENIB) Y EL INHIBIDOR DE MEK (TRAMETINIB), CON EL INHIBIDOR DE BRAF (VEMURAFENIB) EN PACIENTES CON MELANOMA CUTÁNEO NO RESECABLE (ESTADIO IIIC) O METASTÁSIC O (ESTADIO IV) CON LA MUTACIÓN BRAF V600E/K.
Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE
MEK116513
DIFUSIÓN DEL ANESTÉSICO LOCAL EN EL ESPACIO PARAVERTEBRAL TORÁCICO TRAS BLOQUEO PARAVERTEBRAL: ESTUDIO CON TOMOGRAFÍA COMPUTERIZADA CONE BEAM.
Investigador Principal: NURIA GARCÍA GREGORIO
NUR-ROP-2015-01
Cita
Jonczyk M,Althoff C,Slowinski T,Lieker I,Naik M,Auer J,Marcos RG,Duka E,Hamm B,de Bucourt M. Urea-based recirculation validation of the symmetrical palindrome catheter. J Ren Care. 2017. 43. (4):p. 242-246.